Skip to main content

Table 3 NVP-AUY922 biodistribution: pharmacokinetic parameters

From: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

 

Plasma

Tumor

Liver

Muscle

Heart

Lung

Cmax, μmol/L or nmol/g

14.08 ± 4.14

16.36 ± 3.84

30.94 ± 5.58

27.45 ± 6.64

36.86 ± 7.42

48.48 ± 10.11

T 1/2 elimination λ_z, hours

10.3

30

7.7

8

5.6

5.5

AUC(0-8), hours* μmol/L or hours*nmol/g

7.3

345

53

35

32

71

  1. The concentration of NVP-AUY922 was determined by high-pressure liquid chromatography/tandem mass spectrometry after a single intravenous administration of 30 mg/kg to BT-474 tumor-bearing mice. The highest concentration (Cmax), terminal half-life (T 1/2 elimination λ_z), and exposure as determined by the area under the curve (AUC) were determined for each organ, plasma, and BT-474 xenograft (tumor).
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us